@inbook{a71f6d32bdd14a58a98f855779172df8,
title = "In Vitro Immunogenicity Risk Assessment of Therapeutic Proteins in Preclinical Setting",
abstract = "Immunogenicity against therapeutic proteins is a clinical problem in the successful treatment of many diseases and, as such, immunogenicity risk assessment in preclinical setting would be useful to improve safety and efficacy of protein-based therapeutics in the product development stages. Here, we attempted a mechanism-based in vitro study as screening tool to capture clinically observed antibody-based immune response against two representative therapeutic proteins: recombinant human Erythropoietin-alpha (rHuEPO)and recombinant Factor VIII (rFVIII). Flow-cytometry was used to determine the maturation level of dendritic cells (DCs), a primary initiator of T-cell responses. Studies to capture T-lymphocyte proliferation upon challenge with free rFVIII were performed and secretion of immunomodulatory cytokines was analyzed by ELISA assay. These in vitro techniques could be used as risk assessment tool to determine the immunogenic potential of formulations of recombinant proteins in preclinical setting.",
keywords = "Cytokine, Dendritic cell, ELISA, Erythropoietin, Factor VIII, Flow-cytometry, Immunogenicity, Recombinant protein, T-cell proliferation",
author = "Puneet Gaitonde and Balu-Iyer, \{Sathy V.\}",
note = "Publisher Copyright: {\textcopyright} 2011, Springer Science+Business Media, LLC.",
year = "2011",
doi = "10.1007/978-1-61779-012-6\_16",
language = "English",
series = "Methods in Molecular Biology",
publisher = "Humana Press Inc.",
pages = "267--280",
booktitle = "Methods in Molecular Biology",
}